Ahmedabad-based turnkey contractor for hospital critical-care infrastructure (ICUs, NICUs, PICUs, Operation Theatres, dialysis centers) and authorized distributor of medical/diagnostic equipment.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 12.6 | −90.0% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | -4.8 | −25.1 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | -1.7 | −109.6% YoY | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. |
| Return on equity | −17.4 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. | |
| Free cash flow margin | 54.91 | +62.9 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. |
Guidance
4 targets tracked, none judged yet · 4 open · verdicts reflect calls analysed to Q4 FY25.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Order Book Execution Timeline | 5-6 months | Q4 FY25 | Currently, we are having our order book of around INR60 crores, and that is to be executed within, I think, 5 to 6 months | New |
4 of Aprameya Enginee's 4 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 3 more targets are in the full ledger.
Claimed
Qualified
Price
1Y: ₹275 on 24 Oct 2025 → ₹94.7. High ₹352.75 (20 Nov 2025), low ₹79.6 (21 Oct 2026).
Overview
Based on the company's own presentations, annual report and earnings calls.
Aprameya Engineering, established in 2003, designs, sets up and maintains critical hospital infrastructure — ICUs, NICUs, PICUs, Operation Theatres, Dialysis Centers and Prefabricated Wards — on a turnkey basis for government and private hospitals, including hospital design, equipment procurement, supply, commissioning and installation planning. It also supplies high-value medical and diagnostic equipment to hospitals and medical practitioners as an authorized distributor for manufacturers such as Johnson & Johnson, Philips India, Schiller Healthcare, Alan Electronics Systems, ResMed and Karl Storz Endoscopy. The company is not engaged in any manufacturing activity itself; its turnkey/EPC projects (largely for government medical colleges and hospitals) are complemented by after-sales service and AMC/CAMC maintenance contracts.
Segments
Guidance
4 targets tracked, none judged yet · 4 open · verdicts reflect calls analysed to Q4 FY25.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Order Book Execution Timeline | 5-6 months | Q4 FY25 | Currently, we are having our order book of around INR60 crores, and that is to be executed within, I think, 5 to 6 months | New |
Claimed
Qualified
The full ledger
A free account opens 5 company ledgers a month. All 4 tracked commitments, with each call’s wording and source.
Call summaries
Aprameya Enginee Q4 FY25
Aprameya Engineering Limited reported robust financial performance for FY25, with significant year-on-year growth in revenue, EBITDA, and PAT, driven by a strategic shift towards high-margin turnkey projects. The company is actively expanding its geographical footprint and innovating with proprietary healthcare solutions, while also focusing on improving working capital management and reducing debtor days to enhance cash flow.
Read the full callEvery analysed call
Fundamentals
Current values with the period they cover; the trend reads across the 2 fiscal years held (Mar 2025 to Mar 2026).
Financials
Net profit, year on year: −110% (quarter to mar 2026 against mar 2025).
| Line item | Sept 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 9 | 126 | 42 | 13 |
| Expenses | 11 | 101 | 31 | 13 |
| Operating profit | -1 | 26 | 11 | -1 |
| Operating margin | −14.9% | 20.4% | 26.1% | −4.8% |
| Other income | 0 | 0 | 0 | 0 |
| Interest | 1 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 |
| Profit before tax | -2 | 24 | 9 | -2 |
| Tax rate | −24.8% | 25.7% | 26.0% | −12.2% |
| Net profit | -2 | 18 | 7 | -2 |
| EPS (₹ per share) | -0.91 | 9.37 | 3.55 | -0.90 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 7 | 14 | 14 | 19 | 19 | 19 |
| Reserves | 7 | 6 | 9 | 45 | 52 | 50 |
| Borrowings | 14 | 29 | 42 | 30 | 37 | 7 |
| Other liabilities | 20 | 13 | 10 | 49 | 26 | 5 |
| Total liabilities | 49 | 62 | 76 | 144 | 135 | 82 |
| Fixed assets | 2 | 1 | 1 | 1 | 1 | 1 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 47 | 60 | 74 | 143 | 133 | 80 |
| Total assets | 49 | 62 | 76 | 144 | 135 | 82 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 4 | 10 | -13 | -10 | -11 | 31 |
| Cash from investing | 0 | -0 | -2 | -1 | -0 | -4 |
| Cash from financing | -4 | -8 | 13 | 11 | 11 | -28 |
| Net cash flow | -0 | 2 | -2 | 0 | -0 | -0 |
| Free cash flow | 4 | 10 | -14 | -11 | -11 | 31 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 58 | 278 | 195 | 325 | 320 | 368 |
| Inventory days | 122 | 455 | 376 | 74 | — | 81 |
| Days payable | 147 | 1100 | 415 | 146 | — | 95 |
| Cash conversion cycle | 33 | -367 | 157 | 253 | 320 | 354 |
| Working capital days | 36 | 200 | 116 | 153 | 166 | 377 |
| Return on capital employed | 35.3% | 59.3% | 24.9% | 11.8% | 31.1% | 12.6% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
The businesses behind the company’s reported revenue.
Turnkey project Supply contributes 92.1% of reported segment revenue.
Year ended 31 Mar 2026 · Standalone
₹125.04 crore
₹10.67 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| Turnkey project Supply | 125.04 | 92.1% |
| Trading Sales | 10.67 | 7.9% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
Ownership
Promoters hold 74.05% as of Mar 2026; institutions cut 0.07 pts since Sept 2025.
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.
Named in the Mar 2026 filing
Every holder of Aprameya Enginee above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| 36.50% | +0.26 pp | |
| 36.50% | +0.26 pp | |
| 1.21% | unchanged | |
| 0.32% | unchanged | |
| 0.32% | unchanged | |
| 0.21% | unchanged | |
| 0.11% | unchanged | |
| 0.11% | unchanged | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Free account: one company. Everything above stays public.
Write why you follow Aprameya Enginee and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Guides on how to read this kind of business and the numbers that matter.
